It is a very good question and the investing public is entitled to know if this transaction has any influence on the accrued revenue that has been associated with the IFX license dispute. The arbitration and accrued revenue is either in the definitive agreement or not. IDCC does not have to state the exact language because the definitive agreement is contingent on due diligence, but the arbitration is ongoing and IFX has continued to pay both disputed and undisputed royalty on a quarterly basis. Any effect or influence is certainly material with respect to the investing public.
We can assume that Intel is claiming IFX's license for the remaining core patents and they purchased the 1700 patents for cross-licensing purposes. Our analysts were not sharp enough to ask about Intel's obligations to pay royalty for the core patents upon the expiration of the IFX agreement. I wish I had not listened to the CC because the end result is the creation of more unanswered issues on the basis of SM' last comment.
MO
zz
| 
